▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration

#AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, developme...

Business Wire

AI-designed oligos with goal of making therapies safer and more effective for patients with rare and common diseases

SAN DIEGO: #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industry-first AI-Powered Oligo Engineering Engine to design and optimize new drug candidates for Lilly’s named targets on time scales not previously achievable in nucleic acid drug development.

“We are pleased to partner with Lilly to advance our AI-designed oligos with the goal of making therapies safer and more effective for patients. This partnership marks an important milestone for Creyon as we work to advance our RNA-targeted oligo therapy pipeline to the clinic for both rare and common diseases,” said Serge Messerlian, Chairman and Chief Executive Officer of Creyon Bio.

“Creyon has built an industry-first and only oligo engineering engine to efficiently design RNA-targeted oligo therapies using quantum chemistry principles rather than relying on traditional trial-and-error screening processes to significantly accelerate development timelines,” added Swagatam Mukhopadhyay, Co-Founder and Chief Innovation Officer.

Under the terms of the agreement, Creyon will receive a $13 million upfront payment, which includes cash and the purchase of Creyon equity, and Creyon is also eligible to receive over $1 billion in development and commercialization payments provided certain milestones are achieved. Lilly is granted an exclusive license to lead candidates for each target, and if Lilly decides to move forward after certain milestones are achieved, then it will be responsible for further research, development and commercialization.

About Creyon Bio, Inc.

Creyon Bio is a nucleic acid drug development company whose goal is to make oligonucleotide (oligo) therapies safer and more effective for patients with rare and common diseases. The company is working to develop world-class, tissue-specific, RNA-targeted oligo therapies by combining proprietary computational methods with aptamer-based, tissue-specific delivery approaches. Creyon has built the industry-first and only AI-Powered Oligo Engineering Engine that enables a more systematic and cost-effective approach to designing safe and active oligos, moving beyond traditional trial-and-error methods.

To learn more, visit http://www.creyonbio.com/ and follow us on LinkedIn and X.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Securonix Acquires ThreatQuotient to Deliver Industry’s Broadest and Deepest…

Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of…

Confidential Computing Poised for Explosive Growth as Anjuna Secures Three…

Anjuna, a leader in Confidential Computing and AI Data Fusion Clean Rooms, today announced the addition of a new top five global bank to its growing roster…

PubNub Evolves Its Platform with AI-Native Development, Real-Time Moderation,…

PubNub, the leader in real-time interactive apps, unveiled the next evolution of its platform. It introduces AI-native development, real-time decision…

Glean Raises $150M Series F at $7.2B Valuation to Accelerate Enterprise…

Work AI leader Glean today announced it raised $150 million in Series F financing, bringing its valuation to $7.2 billion. The round was led by Wellington…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!